KLOW is a four-peptide blend of GHK-Cu, BPC-157, TB-500, and KPV, sold in one vial and marketed for skin quality, tissue repair, and inflammatory balance. Its benefits belong to those four peptides individually, so the question worth asking is which peptide inside it does what.
That distinction changes how you read every claim on a KLOW product page. One of the four has a human randomized trial behind it. Two have decades of animal work. One is small enough that researchers have built oral delivery systems around it. This guide separates them so you can see which molecule is carrying which promise.
Key Takeaways
The Short Version
KLOW is a compounded blend of four peptides, most often GHK-Cu, BPC-157, TB-500, and KPV in an 80 mg vial split 50/10/10/10.
No published study has tested KLOW as a blend, so every benefit attributed to it traces back to research on one of the four components.
GHK-Cu carries the skin and collagen claims, BPC-157 and TB-500 carry the tissue repair claims, and KPV carries the inflammatory balance claims.
Verify the amount of each peptide on a Certificate of Analysis before buying, and note that TB-500 and BPC-157 are prohibited in sport at all times.
What Is in a KLOW Blend
A standard KLOW vial contains GHK-Cu, BPC-157, TB-500, and KPV together in one lyophilized powder. The most widely sold presentation is 80 mg total, split as 50 mg GHK-Cu and 10 mg each of BPC-157, TB-500, and KPV.
That split is a supplier convention. KLOW has no approved label to standardize it, and vendors also sell 50 mg and 70 mg variants with different ratios. Two vials labeled KLOW can hold different amounts of the same four peptides.
The name itself has no official expansion. It reads most sensibly as KPV added to the older GLOW stack, which pairs GHK-Cu with BPC-157 and TB-500. If a page tells you KLOW stands for something specific, it’s guessing.
| Component | Full name | Size | What research has focused on |
|---|---|---|---|
| GHK-Cu | Glycyl-L-histidyl-L-lysine copper complex | 3 amino acids plus copper | Skin remodeling, collagen, wound repair |
| BPC-157 | Body protection compound 157 | 15 amino acids | Gastric mucosa, tendon, ligament, muscle |
| TB-500 | Synthetic fragment related to thymosin beta-4 | 7 amino acids | Cell migration, angiogenesis, dermal healing |
| KPV | Lysine-proline-valine | 3 amino acids | Inflammatory signaling, colitis models |
If short peptides are new to you, how peptides behave in the body is worth ten minutes before you go further. Size, charge, and stability decide almost everything about how these four are delivered.
Four Peptides, Four Separate Evidence Files
Each component has its own literature, and those bodies of work sit at very different levels of strength. One fact frames all of them: no published study has tested KLOW as a blend. Every KLOW benefit you read about is a component benefit, borrowed.
The peptides themselves are well studied. The combination just hasn’t been, and those are two different claims.
GHK-Cu, the Copper Peptide Behind the Skin Claims
GHK-Cu is the reason KLOW gets described as a skin and appearance blend, and at 50 of the vial’s 80 mg it’s by far the largest ingredient in it. GHK is a naturally occurring human tripeptide that binds copper, and its concentration in plasma falls with age.
Researchers have studied GHK-Cu for a wide set of remodeling activities: attracting repair cells to injured tissue, stimulating collagen and elastin synthesis, and modulating the enzymes that break matrix down (a review of GHK and tissue remodeling). A later review describes GHK stimulating collagen, dermatan sulfate, chondroitin sulfate, and decorin, and reports cosmetic-product findings of improved elasticity, firmness, and skin density (GHK and skin regeneration).
In animal and cell-based work, tripeptide-copper complexes increased collagen expression in cultured fibroblasts and altered the timeline of skin repair in guinea pigs (early tripeptide-copper research). GHK-Cu’s strongest human evidence sits in dermatology and cosmetic testing rather than in large clinical trials, which is a fair reflection of where the research money went. Of the four, it’s the one with the longest track record in products people can buy today.
BPC-157, the Gut and Connective Tissue Peptide
BPC-157 is the component people are chasing when they buy KLOW for recovery. It’s a 15-amino-acid sequence derived from a protein found in human gastric juice, and it stays intact in stomach acid.
In animal research, BPC-157 has been studied for healing across an unusual range of tissues: skin wounds, burns, gastric and intestinal ulcers, tendon, ligament, muscle, and bone (a review of BPC-157 and wound healing). Rat studies on muscle and tendon injury link that effect to angiogenesis, with treated animals showing upregulated VEGF expression and better-organized repair (BPC-157 and angiogenesis in muscle and tendon).
Human data exists but is thin. BPC-157, under the development code PL 14736, reached phase II trials in inflammatory bowel disease with a clean safety profile reported (BPC-157 and ulcerative colitis). If you want the practical version of the oral question, we covered whether BPC-157 capsules work and why blood half-life is the wrong measuring stick.
TB-500, the One That Moves Cells
TB-500 is the component behind KLOW’s tissue repair and angiogenesis claims, and it has something the other three don’t: a completed human randomized trial.
TB-500 is a synthetic peptide related to thymosin beta-4, a naturally occurring protein released by platelets and macrophages after injury. Thymosin beta-4 binds actin and promotes cell migration, including the movement of stem and progenitor cells that form new blood vessels (a review of thymosin beta-4). It also reduces the number of myofibroblasts in wounds, which is linked to less scarring.
In a European double-blind, placebo-controlled trial, topical thymosin beta-4 was tested in patients with venous ulcers for safety, tolerability, and healing (the venous ulcer trial). Phase 2 work has also reported faster repair in pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds, with the peptide described as safe and well tolerated (thymosin beta-4 and dermal healing). Note the route: that human evidence is topical and it’s for thymosin beta-4 itself, not for the TB-500 fragment injected as part of a four-peptide vial.
KPV, the Smallest Piece
KPV is three amino acids long, and its size is exactly why it’s interesting. It’s the C-terminal fragment of alpha-MSH, a hormone with well-mapped anti-inflammatory activity, and it keeps much of that activity in a form small enough to cross the gut wall.
In murine models of inflammatory bowel disease, KPV-treated animals regained body weight earlier, showed fewer inflammatory infiltrates, and had significantly lower myeloperoxidase activity in colon tissue (KPV in murine IBD models). A separate mouse study delivered KPV orally in hyaluronic-acid-functionalized nanoparticles and reported both reduced inflammation and accelerated mucosal healing (orally delivered KPV).
That evidence is animal work, and it’s consistent. We go deeper on dosing, routes, and what the tripeptide does systemically in our guide to KPV peptide benefits.
Where the Four Peptides Overlap
The blend holds together because all four peptides touch the same repair sequence at different points. That’s the real argument for combining them, and it’s a mechanistic argument rather than a clinical one.
- Inflammation first: KPV acts on inflammatory signaling, and GHK-Cu has been studied for suppressing free radicals and pro-inflammatory mediators.
- Blood supply next: TB-500 and BPC-157 have both been linked to angiogenesis in preclinical work, TB-500 through actin binding and cell migration, BPC-157 through VEGF expression.
- Matrix rebuild last: GHK-Cu has been studied for stimulating collagen and proteoglycan synthesis, and BPC-157 for supporting connective tissue repair.
Four peptides, one repair timeline. Whether stacking them produces more than running them separately is an open question, and nobody has run the study that would answer it.
Claimed KLOW Benefits and the Peptide Behind Each One
Almost every KLOW page lists benefits as though the vial produces them. Mapping each claim to the peptide that carries it makes the whole thing readable.
| Claimed benefit | Component carrying it | Strongest evidence behind that component |
|---|---|---|
| Skin firmness, elasticity, fine lines | GHK-Cu | Human cosmetic and dermatology testing |
| Wound and dermal healing | TB-500 and GHK-Cu | Human RCT and phase 2 trials, topical route |
| Tendon, ligament, and muscle recovery | BPC-157 | Animal studies |
| Gut lining and mucosal support | BPC-157 and KPV | Animal studies plus one phase II human trial |
| Inflammatory balance | KPV | Animal studies |
| Hair and follicle support | GHK-Cu | Review-level and cosmetic data |
| Faster overall systemic recovery | The blend | Not studied |
That last row is the honest one, and it’s also the most useful. If a seller promises a systemic outcome from the combination, they’re extrapolating.
How to Get These Peptides Without an Injectable Vial
Three of KLOW’s four peptides are available in oral capsule formulas with disclosed amounts, which solves the main problem with a compounded vial: you can’t verify what’s in it.
BioGutPro is the closest match on our shelf. It carries BPC-157 at 1,000 mcg, KPV at 500 mcg, and GHK-Cu at 2 mg per serving, alongside N-acetyl larazotide, CoreBiome tributyrin, zinc L-carnosine, and a sodium bicarbonate buffer that protects acid-sensitive peptides on the way down. Three of KLOW’s four peptides, printed on the label with amounts, in a formula built around the gut lining.
If your goal is training recovery rather than digestion, BioRestore pairs BPC-157 arginine salt at 1,000 mcg with palmitoylethanolamide, hyaluronic acid, and the same buffering approach. It’s the recovery-side answer to the same question.
Neither formula contains TB-500, and that’s deliberate. TB-500 has no consumer supplement pathway, for reasons the next section covers.
Sourcing, Dosing, and Regulatory Status
Anything you take should be traceable to a Certificate of Analysis with a batch number, a purity figure, and an identity confirmation. That’s the single most valuable habit in this category, because compounded blends are sold by weight and appearance and very little else.
A few facts worth carrying into any purchase decision:
- Ratios vary between sellers: a KLOW vial’s split is set by the supplier, so compare milligrams per peptide rather than total milligrams.
- TB-500 is banned in sport at all times: thymosin beta-4 and its derivatives, TB-500 included, sit in section S2 of the WADA Prohibited List. BPC-157 is prohibited at all times as well, under S0.
- FDA compounding status is still moving: in September 2023 the FDA placed BPC-157, KPV, and TB-500 in Category 2 of its 503A bulk drug substances list. All three came back out of Category 2 in April 2026 for re-evaluation, and in July 2026 the agency’s Pharmacy Compounding Advisory Committee voted narrowly in favor of all three. Those votes are recommendations. None of the three has been added to the 503A list yet.
We’ve written about why this regulatory picture is messier than it needs to be in our take on a better way to regulate peptides.
BPC-157 and KPV can interact with medications that affect inflammation, pain signaling, immune function, or gut motility. If you take NSAIDs, immunosuppressants, or prescription GI medication, talk to your clinician before adding either one.
Frequently Asked Questions
What does KLOW peptide stand for?
KLOW has no official acronym expansion. The name is a supplier convention, and it reads as KPV added to the GLOW stack, which contains GHK-Cu, BPC-157, and TB-500. Any page that spells out a meaning for each letter is filling in a blank.
What are the main KLOW peptide benefits?
The benefits attributed to KLOW are skin quality and collagen support from GHK-Cu, soft tissue and gut lining support from BPC-157, tissue repair and cell migration from TB-500, and inflammatory balance from KPV. Each belongs to a component, since the blend has not been studied as a blend.
Is KLOW the same as GLOW?
No. GLOW typically contains three peptides: GHK-Cu, BPC-157, and TB-500. KLOW adds KPV as a fourth. A separate compounded IV product also called GLOW uses GHK-Cu with glutathione and vitamin C, so check the actual component list rather than the name.
Can you take KLOW orally?
KLOW vials are formulated for reconstitution and injection, not oral use. KPV and BPC-157 have both been studied in oral delivery contexts, which is why they show up in capsule formulas, while GHK-Cu is most commonly used topically and TB-500 has no oral consumer format.
Is KLOW safe for athletes who get tested?
No. TB-500 falls under section S2 of the WADA Prohibited List as a thymosin beta-4 derivative, and BPC-157 is prohibited under S0. Both are banned at all times, in and out of competition.
How long does it take to see results from these peptides?
Timelines in the research vary by tissue. Skin and cosmetic endpoints for GHK-Cu are usually measured over 4 to 12 weeks, and gut lining and connective tissue support in capsule formulas is generally assessed over 30 to 90 days of consistent use.
Read More From the BioLongevity Blog
- KPV vs BPC-157: Calming Inflammation or Rebuilding Tissue?
- Can Peptides Be Taken Orally? Size Is the Deciding Factor
- Best Leaky Gut Supplements: What the Evidence Shows
If KLOW appeals to you because of what those peptides do rather than because of the vial they come in, BioGutPro is the version you can actually verify. It puts BPC-157, KPV, and GHK-Cu on a printed label at disclosed amounts, manufactured in a cGMP facility and third-party tested, with the batch documentation published on our Certificates of Analysis page. Read the COA first, then decide. That’s the standard this category has been missing.
Ask a qualified clinician before starting any supplement if you are pregnant, nursing, taking medication, or managing a medical condition.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. DOI
- Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015;2015:648108. DOI
- Buffoni F, Pino R, Dal Pozzo A. Effect of tripeptide-copper complexes on the process of skin wound healing and on cultured fibroblasts. Archives Internationales de Pharmacodynamie et de Therapie. 1995;330(3):345-360. PubMed
- Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology. 2021;12:627533. DOI
- Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009;60(Suppl 7):191-196. PubMed
- Sikiric P, Seiwerth S, Rucman R, et al. Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157. Current Medicinal Chemistry. 2012;19(1):126-132. DOI
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta-4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. DOI
- Guarnera G, De Rosa A, Camerini R. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Annals of the New York Academy of Sciences. 2007;1112:407-412. DOI
- Kleinman HK, Sosne G. Thymosin beta-4 promotes dermal healing. Vitamins and Hormones. 2016;102:251-275. DOI
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331. DOI
- Xiao B, Xu Z, Viennois E, et al. Orally targeted delivery of tripeptide KPV via hyaluronic acid-functionalized nanoparticles efficiently alleviates ulcerative colitis. Molecular Therapy. 2017;25(7):1628-1640. DOI